Latest Regulatory News

Yowie Group Ltd has formally applied to the Takeovers Panel for a review of its recent decision involving Keybridge Capital Limited, signaling ongoing regulatory scrutiny in this corporate governance matter.

Canadian Phosphate Limited has obtained a 10,000-tonne bulk sample permit for its Barnes deposit at the Fernie Project, marking a significant step toward establishing a domestic phosphate supply in British Columbia. Additional permits are underway, supporting the company’s growth and critical minerals strategy.

Codeifai Limited has agreed to acquire its main competitor Trust Codes Global Limited, significantly expanding its footprint and product capabilities ahead of the 2027 global shift to 2D barcodes.

Simble Solutions Limited has voluntarily suspended its ASX trading pending a capital raising announcement, signaling a significant funding move for the software company.

S2 Resources Limited launches a discounted Share Purchase Plan allowing eligible shareholders to invest up to $30,000, accompanied by free attaching options exercisable at $0.11. The capital raise supports exploration across key Australian projects.

Krakatoa Resources secures $1.3 million via placement to fund a maiden diamond drilling campaign at its Zopkhito Project in Georgia, aiming to upgrade foreign resource estimates to JORC standards.

Karoon Energy has successfully acquired 100% interests in six offshore blocks in Brazil’s Santos Basin, reinforcing its strategic position and increasing its 2025 capital expenditure guidance to US$120-140 million.

Blaze Minerals has inked a binding deal to acquire a major interest in the Loulombo Base Metals Project in the Republic of Congo, backed by a $2.52 million capital raise to fund exploration and development.

Morella Corporation has initiated a pioneering rubidium extraction study with Edith Cowan University and secured key approvals for development drilling at its Mt Edon Project, setting the stage for a maiden mineral resource estimate.

Lumos Diagnostics has enrolled 500 patients in its FebriDx CLIA waiver clinical study, unlocking a significant milestone payment from BARDA and moving closer to FDA approval that could open a US$1 billion market.

CLINUVEL’s Phase II pilot study reveals afamelanotide monotherapy does not trigger repigmentation in vitiligo patients, underscoring the necessity of adjunct NB-UVB phototherapy.

Mayne Pharma shareholders have overwhelmingly approved the scheme of arrangement for Cosette Pharmaceuticals to acquire the company at $7.40 per share, despite ongoing legal challenges and regulatory approvals still pending.